| Home | E-Submission | Sitemap | Contact Us |  
JPTM > Ahead-of Print

doi: https://doi.org/10.4132/jptm.2019.02.03    [Epub ahead of print]
Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis
Jung-Soo Pyo1, Nae Yu Kim2, Won Jin Cho3
1Department of Pathology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea
2Department of Internal Medicine, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea
3Department of Urology, Chosun University Hospital, Chosun University School of Medicine, Gwangju, Korea
Corresponding Author: Won Jin Cho ,Tel: +82-62-220-3210, Fax: +82-62-232-3210, Email: uro2097@gmail.com
Received: December 31, 2018;  Revised: February 1, 2019  Accepted: February 3, 2019.  Published online: March 5, 2019.

Although the correlation between low claudin-1 expression and worse prognosis has been reported, details on the prognostic implications of claudin-1 expression in various malignant tumors remain unclear. The present study aimed to elucidate the prognostic roles of claudin-1 immunohistochemistry (IHC) in various malignant tumors through a meta-analysis.
The study included 2,792 patients from 22 eligible studies for assessment of the correlation between claudin-1 expression and survival rate in various malignant tumors. A subgroup analysis based on the specific tumor and evaluation criteria of claudin-1 IHC was conducted.
Low claudin-1 expression was significantly correlated with worse overall survival (OS) (hazard ratio [HR] 1.851, 95% confidence interval [CI] 1.506–2.274) and disease-free survival (DFS) (HR 2.028, 95% CI 1.313–3.134) compared to high claudin-1 expression. Breast, colorectal, esophageal, gallbladder, head and neck, and lung cancers, but not cervical, liver or stomach cancers, were significantly correlated with worse OS. Breast, colorectal, esophageal, and thyroid cancers with low claudin-1 expression were associated with poorer DFS. In the lower cut-off subgroup (< 17.5 25.0%) with respect to claudin-1 IHC, low claudin-1 expression was significantly correlated with worse OS and DFS.
Taken together, low claudin-1 IHC expression is significantly correlated with worse survival in various malignant tumors. More detailed criteria for claudin-1 IHC expression in various malignant tumors are needed for application in daily practice.
Key Words: claudin-1; immunohistochemistry; prognosis; malignancy; meta-analysis